Recurrent stroke and cardiac risks after first ischemic stroke - The Northern Manhattan Study

被引:245
作者
Dhamoon, MS
Sciacca, RR
Rundek, T
Sacco, RL
Elkind, MSV
机构
[1] Columbia Univ, Joseph P Mailman Sch Publ Hlth, Mt Sinai Sch Med, New York, NY USA
[2] Columbia Univ, Joseph P Mailman Sch Publ Hlth, Dept Med, New York, NY USA
[3] Columbia Univ, Joseph P Mailman Sch Publ Hlth, Dept Neurol, New York, NY USA
[4] Columbia Univ, Joseph P Mailman Sch Publ Hlth, Sergievsky Ctr, New York, NY USA
[5] Columbia Univ, Joseph P Mailman Sch Publ Hlth, Coll Phys & Surg, New York, NY USA
[6] Columbia Univ, Joseph P Mailman Sch Publ Hlth, Div Epidemiol, New York, NY USA
关键词
D O I
10.1212/01.wnl.0000201253.93811.f6
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Few population-based studies with long-term follow-up have compared risk of recurrent stroke and cardiac events after first ischemic stroke. The relative risk of these two outcomes may inform treatment decisions. Methods: In the population-based Northern Manhattan Study, first ischemic stroke patients age 40 or older were prospectively followed for recurrent stroke, myocardial infarction (MI), and cause-specific mortality. Fatal cardiac events were defined as death secondary to MI, congestive heart failure, sudden death/arrhythmia, and cardiopulmonary arrest. Risk of events (with 95% CIs) was calculated using Kaplan-Meier survival analysis and adjusted for sex and age using Cox proportional hazard models. Results: Mean age (n = 655; median follow-up 4.0 years) was 69.7 +/- 12.7 years. The risk of recurrent stroke was more than twice that of cardiac events (including nonfatal MI) at 30 days and approximately twice cardiac risk at 5 years. The age- and sex-adjusted 5-year risk of fatal or nonfatal recurrent stroke was 18.3% (14.8 to 21.7%), and the 5-year risk of MI or fatal cardiac event was 8.6% (6.0 to 11.2%). The adjusted 5-year risk of nonfatal stroke (14.8%, 11.6 to 17.9%) was approximately twice as high as fatal cardiac events (6.4%, 4.1 to 8.6%) and four times higher than risk of fatal stroke (3.7%, 2.1 to 5.4%). Conclusions: Cardiac mortality is nearly twice as high as mortality owing to recurrent stroke, but long-term risk of all stroke, fatal or nonfatal, is approximately twice the risk of all cardiac events. The high risk of nonfatal recurrent stroke reinforces the importance of therapies aimed at preventing stroke recurrence in addition to preventing cardiac events.
引用
收藏
页码:641 / 646
页数:6
相关论文
共 48 条
  • [1] Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke - A scientific statement for healthcare professionals from the stroke council and the council on clinical cardiology of the American Heart Association/American Stroke Association
    Adams, RJ
    Chimowitz, MI
    Alpert, JS
    Awad, IA
    Cerqueria, MD
    Fayad, P
    Taubert, KA
    [J]. CIRCULATION, 2003, 108 (10) : 1278 - 1290
  • [3] [Anonymous], 1998, JAMA, V279, P1265
  • [4] [Anonymous], 1990, Stroke, V21, P1122
  • [5] [Anonymous], 1993, Stroke, V24, P543
  • [6] [Anonymous], 1991, Lancet, V338, P1345
  • [7] [Anonymous], 1993, LANCET, V342, P1255, DOI DOI 10.1016/0140-6736(93)92358-Z
  • [8] THE FREQUENCY, CAUSES AND TIMING OF DEATH WITHIN 30 DAYS OF A 1ST STROKE - THE OXFORDSHIRE-COMMUNITY-STROKE-PROJECT
    BAMFORD, J
    DENNIS, M
    SANDERCOCK, P
    BURN, J
    WARLOW, C
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1990, 53 (10) : 824 - 829
  • [9] Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial
    Bath, PMW
    Lindenstrom, E
    Boysen, G
    De Deyn, P
    Friis, P
    Leys, D
    Marttila, R
    Olsson, JE
    O'Neill, D
    Orgogozo, JM
    Ringelstein, B
    van der Sande, JJ
    Turpie, AGG
    [J]. LANCET, 2001, 358 (9283) : 702 - 710
  • [10] Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study
    Berge, E
    Abdelnoor, M
    Nakstad, PH
    Sandset, PM
    [J]. LANCET, 2000, 355 (9211) : 1205 - 1210